IKT INHIBIKASE THERAPEUTICS INC Management Changes 8-K Filing 2024 - Appointment of CFO Inhibikase Therapeutics, Inc. filed an Amendment No. 1 to their Original 8-K, announcing the appointment of Garth Lees-Rolfe as Chief Financial Officer and providing information about his compensation arrangements.Get access to all SEC 8-K filings of the INHIBIKASE THERAPEUTICS INC